# Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

> **NCT02935309** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Rectal Cancer
- Rectal Adenocarcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Capecitabine
- **RADIATION:** External Radiation Therapy (XRT)

## Key facts

- **NCT ID:** NCT02935309
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-14
- **Primary completion:** 2019-10-11
- **Final completion:** 2020-05-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935309, "Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02935309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*